NEW YORK, — Britain became the first Western country to approve a COVID-19 vaccine, jumping ahead of the United States and Europe after its regulator cleared a shot developed by Pfizer and BioNTech for emergency use in record time.
Pfizer, with partner BioNTech SE, and rival Moderna have released trial data showing their COVID-19 vaccines to be about 95% effective at preventing the illness, while AstraZeneca last month said its vaccine was on average about 70% effective.
The companies have said distribution could begin almost immediately after any approval, with governments around the world to decide who gets them and in what order. The following is an outline of the process:
WHEN WILL COMPANIES ROLL OUT A VACCINE?
Pfizer, Moderna and AstraZeneca have already started manufacturing their vaccines, and the Pfizer-BioNTech vaccine will be rolled out from early next week in Britain.
This year, Pfizer said it would have enough to inoculate 25 million people, Moderna will have enough for 10 million people and AstraZeneca will have enough for more than 100 million people.
The U.S. Department of Defense and the Centers for Disease Control and Prevention (CDC) will manage distribution in the United States, with some 20 million people expected to be inoculated by the end of the year.
Some 60 million to 70 million doses of COVID-19 vaccine could be available per month beginning in January and most Americans will have access to shots by mid-2021, the government said on Tuesday.
In the European Union, it is up to each country in the 27-member bloc to start distributing vaccines to their populations.
WHO WOULD GET AN APPROVED VACCINE AND WHEN IN THE UNITED STATES?
The U.S. Food and Drug Administration (FDA) will make a decision on emergency use authorization on the Pfizer/BioNTech vaccine in days or weeks after a panel of outside advisors meets on Dec. 10 to discuss whether to recommend it. The FDA often but not always follows the panel’s advice.
Upon FDA authorization, the CDC is planning that first in line for vaccinations would be about 21 million healthcare workers and 3 million residents in long-term care facilities.
Essential workers, a group of 87 million people who do crucial jobs that cannot be done from home, are the likely next group. This includes firefighters, police, school employees, transport workers, food and agriculture workers and food service employees.
Around 100 million adults with high-risk medical conditions and 53 million adults over the age of 65, also considered at higher risk of severe disease, are the next priority.
U.S. public health officials said vaccines would be generally available to most Americans in pharmacies, clinics and doctors offices starting in April so that anyone who wants a shot can have one by the end of June.
It is unclear when a vaccine will be available for children. Pfizer and BioNTech have started testing their vaccine in volunteers as young as 12.
WHEN WILL A VACCINE BE AVAILABLE IN OTHER COUNTRIES?
Britain will start a roll-out of the Pfizer-BioNTech vaccine this month. The country had ordered 40 million doses – enough for just under a third of the population.
Older care home residents and their carers will be the highest priority to receive the vaccine, followed by those over 80 years of age and frontline health workers.
The European Union (EU), Japan, Canada and Australia are all running rapid vaccine regulatory processes.
The EU drugs regulator, the European Medicines Agency, said it could give conditional marketing approval for Pfizer’s vaccine by Dec. 29 and make a decision on Moderna’s by Jan. 12.
Most countries in the region have said the first vaccines would go to the elderly and vulnerable and frontline workers.
Many of AstraZeneca’s doses this year are expected to go to Britain, where health officials have said that if approved they could begin vaccinating people in December.
Countries say they are buying vaccines via the European Commission’s joint procurement scheme, which has deals for six different vaccines and nearly 2 billion doses.
Delivery timelines vary and most countries are still drawing up plans for distributing and administering shots.
Italy expects to receive the first deliveries of the Pfizer-BioNTech shot and AstraZeneca’s shot early next year. Spain plans to give vaccines in January.
Hungary’s foreign minister said doses would land in the spring at the earliest.
Germany, home to BioNTech, expects to roll out shots in early 2021 with mass vaccination centres in exhibition halls, airport terminals and concert venues. It will also use mobile teams for care homes.
WHEN WILL DEVELOPING COUNTRIES HAVE ACCESS TO VACCINES?
COVAX, a programme led by the World Health Organization and the GAVI vaccine group to pool funds from wealthier countries and non-profits to buy and distribute vaccines to dozens of poorer countries, has raised $2 billion.
Its first goal is to vaccinate 3% of the people in these countries with a final goal of reaching 20%. It has signed a provisional agreement to buy AstraZeneca’s vaccine, which does not require storage in specialized ultra cold equipment like the Pfizer vaccine.
It is expected, but not certain, that less wealthy countries in Africa and Southeast Asia, such as India, will receive vaccines at low or no cost under this programme in 2021. Other countries, such as those in Latin America, may buy vaccines through COVAX. Several are also striking supply deals directly with drugmakers.
HOW MUCH WILL IT COST?
Vaccine makers and governments have negotiated varying prices, not all of which are public. Governments have paid from a few dollars per AstraZeneca shot to up to $50 for the two-dose Pfizer regimen. Many countries have said they will cover the cost of inoculating their residents.
— Reporting by Carl O’Donnell and Julie Steenhuysen; Additional reporting by Michael Erman in New York, Caroline Copley in Berlin, Francesco Gaurascio in Brussels, Josephine Mason in London, Krisztina Than in Budapest, Tsvetelia Tsolova in Sofia and Pushkala Aripaka in Bengaluru; Editing by Caroline Humer, Bill Berkrot, Josephine Mason and Alex Richardson
